SIRS-Lab, Analytik Jena partner in molecular sepsis diagnostics

Jun 15 2010

SIRS-Lab GmbH and Analytik Jena AG, also based in Jena, will be strengthened by working together in the field of molecular sepsis diagnostics. As part of this cooperation, Analytik Jena subsidiary AJ Innuscreen GmbH will provide the partner with a platform for automated isolation of nucleic acids with the associated reagent system worth almost half a million euro.

“In the field of sepsis diagnosis, speed plays a vital role in identifying infections and detecting pathogens. Analytik Jena's cooperation with SIRS-Lab offers great potential for the challenging area of diagnostics”

"Analytik Jena provides us with special reagents and instruments, tailored to our developments, for the fully automated extraction of DNA in whole blood samples. The clinical studies currently underway to validate the test should create the conditions to start marketing our sepsis diagnostics very soon", explained Barbara Staehelin, CEO of SIRS-Lab GmbH.

Analytik Jena AG concentrates its biotechnological expertise in the Life Science division. Its service includes automated individual and complete solutions for molecular diagnostics. The wide range of products is made possible by synergies between Analytik Jena and its subsidiaries AJ Cybertron, AJ Innuscreen, AJ Roboscreen, AJ eBiochip, CyBio AG and Biometra GmbH.

"In the field of sepsis diagnosis, speed plays a vital role in identifying infections and detecting pathogens. Analytik Jena's cooperation with SIRS-Lab offers great potential for the challenging area of diagnostics", commented Klaus Berka, CEO of Analytik Jena AG.

SIRS-Lab is a biotechnology company which develops and produces molecular diagnostic tests for life-threatening infections. One significant partner is the university hospital Jena, which recently received the green light to develop an integrated research center for sepsis. This development is focused primarily on enabling rapid and targeted antibiotic therapy for sepsis.